Lin, C., Garralda, E., Schöffski, P., Hong, D. S., Siu, L. L., Martin, M., . . . Braud, F. D. A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies. Taylor & Francis Group.
Chicago Style (17th ed.) CitationLin, Chia-Chi, et al. A Phase 2, Multicenter, Open-label Study of Anti-LAG-3 Ieramilimab in Combination with Anti-PD-1 Spartalizumab in Patients with Advanced Solid Malignancies. Taylor & Francis Group.
MLA (9th ed.) CitationLin, Chia-Chi, et al. A Phase 2, Multicenter, Open-label Study of Anti-LAG-3 Ieramilimab in Combination with Anti-PD-1 Spartalizumab in Patients with Advanced Solid Malignancies. Taylor & Francis Group.
Warning: These citations may not always be 100% accurate.